Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,586JPY
8:11pm EDT
Change (% chg)

¥34 (+1.33%)
Prev Close
¥2,552
Open
¥2,592
Day's High
¥2,592
Day's Low
¥2,580
Volume
100,900
Avg. Vol
2,125,197
52-wk High
¥2,750
52-wk Low
¥2,192

Latest Key Developments (Source: Significant Developments)

Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.
Monday, 13 Mar 2017 03:16am EDT 

Sosei Group Corp <4565.T>:Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13.  Full Article

Amring Pharmaceuticals says acquired six ANDAs from Luitpold Pharmaceuticals, Alphaforce L.L.P.
Thursday, 9 Mar 2017 11:59am EST 

Amring Pharmaceuticals Inc : Amring pharmaceuticals inc - acquired six andas from luitpold pharmaceuticals inc and alphaforce l.l.p. .Amring pharmaceuticals inc - acquired andas include niche otic and ophthalmic pharmaceuticals.  Full Article

EMA recommends approval of Daiichi Sankyo's anticoagulant
Friday, 24 Feb 2017 07:00am EST 

EU Medicines Agency: EU medicines Agency recommendations for February 2017 . EU Medicines Agency recommends approval Of Daiichi Sankyo's anticoagulant Edoxaban . EU Medicines Agency says adopted positive opinion recommending changes to the terms of the marketing authorisation for the medicinal product Darzalex . EU Medicines Agency recommends approval of Hospira UK Limited's Pemetrexed for treatment of non-small cell lung cancer Source (http://bit.ly/2lCHPks) Further company coverage: [4568.T] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial
Friday, 17 Feb 2017 06:00am EST 

ArQule Inc - : Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma . Study of tivantinib in hepatocellular carcinoma (hcc) did not meet its primary endpoint of improving overall survival .Primary endpoint of study is overall survival.  Full Article

Charleston Laboratories and Daiichi Sankyo receive complete response letter from FDA for CL-108
Friday, 3 Feb 2017 11:00am EST 

Charleston Laboratories : Charleston laboratories, inc. And daiichi sankyo, inc. Receive complete response letter from fda for new drug application for cl-108 (hydrocodone, acetaminophen, promethazine) tablets for oral use .Charleston laboratories - crl stated nda in its present form was not approved and provided guidance on information needed to resolve matters identified.  Full Article

Kite Pharma establishes strategic partnership with Daiichi Sankyo
Monday, 9 Jan 2017 04:23pm EST 

Kite Pharma Inc : Kite Pharma establishes strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (kte-c19) in Japan . Kite Pharma - Daiichi Sankyo will make an upfront payment to kite of $50 million . Kite Pharma says will be eligible to receive future payments totaling up to $200 million for development and commercial milestones . Kite Pharma says is also entitled to receive sales royalties in the low to mid double digit range .Kite pharma - under terms, Daiichi Sankyo will be responsible for development and commercialization of axicabtagene ciloleucel in Japan.  Full Article

R&I affirms Daiichi Sankyo Co Ltd's rating at "AA" and announces negative outlook -R&I
Tuesday, 27 Dec 2016 01:35am EST 

Daiichi Sankyo Co Ltd <4568.T> : Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA" -R&I .Rating outlook negative -R&I.  Full Article

U.S. FDA grants designation for HER2-targeting antibody drug conjugate DS-8201
Thursday, 1 Dec 2016 08:00am EST 

Daiichi Sankyo Co Ltd <4568.T>: u.s. Fda grants fast track designation for her2-targeting antibody drug conjugate ds-8201 for her2-positive metastatic breast cancer .Daiichi sankyo -fda grantd fast track designation to investigational her2-targeting antibody drug conjugate ds-8201 for her2-positive metastatic breast cancer.  Full Article

Daiichi Sankyo Co and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond
Tuesday, 25 Oct 2016 09:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Daiichi And Inspirion Delivery Sciences LLC announce U.S. Licensing agreement for morphabond formulated with sentrybond abuse-deterrent technology . Under terms of agreement inspirion will receive an upfront payment .Inspiron will also receive milestone payments and royalties under terms of agreement.  Full Article

Daiichi Sankyo Co Ltd, Dana-Farber Cancer Institute today announce lung cancer research collaboration
Wednesday, 12 Oct 2016 08:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Daiichi Sankyo Co Ltd - co, Dana-Farber Cancer Institute today announced a preclinical research collaboration focused on lung cancer .Daiichi Sankyo Co Ltd - financial terms of agreement were not disclosed.  Full Article

More From Around the Web

BRIEF-Daiichi Sankyo announces new analyses

* Daiichi Sankyo Inc announces new analyses of once-daily savaysa (edoxaban) in patients with non-valvular atrial fibrillation to be presented at the acc 66th annual scientific session